Bloomberg Law
December 4, 2017, 8:16 PM UTC

CVS-Aetna Deal May Hinge on Antitrust Approach Under Trump

By Robert Langreth, David McLaughlin, and Zachary Tracer


  • Companies announced $67.5 billion takeover on Sunday


  • Aetna shares trade below $207 price, signaling investor worryBy Robert Langreth, David McLaughlin and Zachary Tracer

CVS Health Corp.’s $67.5 billion takeover of Aetna Inc. will test the Trump administration’s approach to far-reaching corporate takeovers, just weeks after the U.S. government sued to block a major telecommunications merger.

The health-care deal unveiled Sunday would create an industry giant with over $240 billion in annual sales with a hand in insurance, prescription drug plan administration, retail pharmacies and corner clinics. The companies said the combination will save $750 million in costs and bring consumers better, ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.